The results of a clinical study on the combination therapy of our UI-201 and TCR gene-modified T-cell therapy has been published as an academic paper in the online edition of the International Journal of Cancer.
Ishihara, M, Nishida, Y, Kitano, S, et al. A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma. Int J Cancer. 2023; 1- 13. doi:10.1002/ijc.34453